Doximity, Inc. (DOCS): Results of Operations and Financial Condition
Doximity, Inc. (DOCS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 doximity-2026630xex991.htm EX-99.1 Document Exhibit 99.1 Doximity Announces Fiscal 2027 First Quarter Financial Results Total revenues of $156.6 million, up 7% year-over-year Net income of $24.3 million, margin of 16% Adjusted EBITDA of $74.8 million, margin of 48% SAN
How this was made
The 30-second read
Why it matters
DOCS provides both historical quarter results and forward guidance. The mix of revenue growth with weaker net income, adjusted EBITDA, and free cash flow creates a two-sided setup for near-term estimate revisions and sentiment.
Market read
Fresh earnings and guidance numbers, including Q2 and FY27 revenue and adjusted EBITDA ranges, are directly tradable for DOCS and can drive revisions to forward models.
What to watch
Traders may over-focus on net income and EBITDA declines; the guidance ranges for Q2 and FY27 adjusted EBITDA could be the more important signal for forward estimates and valuation.
Background
This is an SEC 8-K with Exhibit 99.1 covering Doximity’s fiscal 2027 first quarter ended June 30, 2026, plus updated guidance for Q2 and FY27.
Ticker impact
Doximity reported fiscal 2027 Q1 results and updated guidance, including revenue $156.6M (+7% YoY) and Q2 revenue $170M-$171M.
Likely choppy reaction risk: upside from revenue/engagement growth, offset by weaker net income, EBITDA, and free cash flow versus last year.
The filing provides fresh, decision-relevant numbers: Q1 revenue growth but lower net income and adjusted EBITDA, plus a 32% decline in operating cash flow and 34% decline in free cash flow. It also updates Q2 and FY27 revenue and adjusted EBITDA ranges, which can re-anchor expectations.
Market effects
AI-enabled workflow and search engagement metrics may influence sentiment toward digital health and physician network platforms.
Limited, primarily company-specific for a US-listed name.
Low, as the disclosure is US-focused and not tied to cross-border regulatory or macro events.
Counterpoint
The year-over-year profitability and cash-flow declines could be temporary (timing of expenses or working capital), while revenue and prescriber engagement growth may still support multiple expansion.
Key entities
- companyDoximity, Inc.
NYSE-listed digital platform for US medical professionals, reporting fiscal 2027 Q1 results and updated guidance.
- tickerDOCS
Doximity’s common stock ticker referenced in the filing.
